In vivo efficacy of photodynamic therapy in three new xenograft models of human retinoblastoma

Photodiagnosis and Photodynamic Therapy

Volumn 7, Issue 4, 2010, Pages 275-283

  Aerts, Isabelle ^a   Leuraud, Pascal ^a   Blais, Jocelyne ^b   Pouliquen, Anne lise ^a   Maillard, Philippe ^b   Houdayer, Claude ^a,c   Couturier, Jérôme ^a   Sastre Garau, Xavier ^a   Grierson, David ^b   Doz, François ^a,d   Poupon, Marie France ^a  

^a INSTITUT CURIE   (France)

^b CNRS   (France)

^c FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

^d UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

MTHPC; Photodynamic therapy; Preclinical; Retinoblastoma; Verteporfin; Xenograft

Indexed keywords

CARBOPLATIN; ETOPOSIDE; TEMOPORFIN; TETRAKIS(3 HYDROXYPHENYL)CHLORIN; VERTEPORFIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HISTOPATHOLOGY; MOUSE; NONHUMAN; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RETINOBLASTOMA; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; CELL LINE, TUMOR; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; MALE; MESOPORPHYRINS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; PHOTOCHEMOTHERAPY; PHOTOSENSITIZING AGENTS; PORPHYRINS; RETINAL NEOPLASMS; RETINOBLASTOMA; TRANSPLANTATION, HETEROLOGOUS;

MUS; MUS MUSCULUS;

EID: 78649629592     PISSN: 15721000     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pdpdt.2010.09.003     Document Type: Article

References (52)

1. Abramson D.H., Schefler A.C. Update on retinoblastoma. Retina 2004, 24:828-848.
2. Friend S.H., Bernards R., Rogelj S., et al. A human DNA segment with properties of the gene that predisposes to retinoblastoma and osteosarcoma. Nature 1986, 323:643-646.
3. Aerts I., Pacquement H., Doz F., et al. Outcome of second malignancies after retinoblastoma: a retrospective analysis of 25 patients treated at the Institut Curie. Eur J Cancer 2004, 40:1522-1529.
4. Wong F.L., Boice J.D., Abramson D.H., et al. Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. JAMA 1997, 278:1262-1267.
5. Murphree A.L., Villablanca J.G., Deegan W.F., et al. Chemotherapy plus local treatment in the management of intraocular retinoblastoma. Arch Ophthalmol 1996, 114:1348-1356.
6. Lumbroso L., Doz F., Urbieta M., et al. Chemothermotherapy in the management of retinoblastoma. Ophthalmology 2002, 109:1130-1136.
7. Shields J.A., Shields C.L., De Potter P. Cryotherapy for retinoblastoma. Int Ophthalmol Clin 1993, 33:101-105.
8. Shields C.L., Shields J.A., Cater J., Othmane I., Singh A.D., Micaily B. Plaque radiotherapy for retinoblastoma: long-term tumor control and treatment complications in 208 tumors. Ophthalmology 2001, 108:2116-2121.
9. Chantada G.L., Fandino A.C., Raslawski E.C., et al. Experience with chemoreduction and focal therapy for intraocular retinoblastoma in a developing country. Pediatr Blood Cancer 2005, 44:455-460.
10. Levy C., Doz F., Quintana E., et al. Role of chemotherapy alone or in combination with hyperthermia in the primary treatment of intraocular retinoblastoma: preliminary results. Br J Ophthalmol 1998, 82:1154-1158.
11. Rodriguez-Galindo C., Wilson M.W., Haik B.G., et al. Treatment of intraocular retinoblastoma with vincristine and carboplatin. J Clin Oncol 2003, 21:2019-2025.
12. Shields C.L., Shields J.A., Meadows A.T. Chemoreduction for retinoblastoma may prevent trilateral retinoblastoma. J Clin Oncol 2000, 18:236-237.
13. Kleinerman R.A., Tucker M.A., Tarone R.E., et al. Risk of new cancers after radiotherapy in long-term survivors of retinoblastoma: an extended follow-up. J Clin Oncol 2005, 23:2272-2279.
14. Dougherty T.J., Gomer C.J., Henderson B.W., et al. Photodynamic therapy. J Natl Cancer Inst 1998, 90:889-905.
15. Brown S.B., Brown E.A., Walker I. The present and future role of photodynamic therapy in cancer treatment. Lancet Oncol 2004, 5:497-508.
16. Robertson C.A., Evans D.H., Abrahamse H. Photodynamic therapy (PDT): a short review on cellular mechanisms and cancer research applications for PDT. J Photochem Photobiol B 2009, 96:1-8.
17. Castano A.P., Demidova T.N., Hamblin M.R. Mechanisms in photodynamic therapy: part two - cellular signaling, cell metabolism and modes of cell death. Photodiagn Photo 2005, 2:1-23.
18. Almeida R.D., Manadas B.J., Carvalho A.P., Duarte C.B. Intracellular signaling mechanisms in photodynamic therapy. Biochim Biophys Acta 2004, 1704:59-86.
19. Winther J., Overgaard J. Experimental studies of photodynamic therapy in a retinoblastoma-like tumour. Acta Ophthalmol Suppl 1987, 182:140-143.
20. Ohnishi Y., Yamana Y., Minei M. Photoradiation therapy using argon laser and a hematoporphyrin derivative for retinoblastoma - a preliminary report. Jpn J Ophthalmol 1986, 30:409-419.
21. Reid T.W., Albert D.M., Rabson A.S., et al. Characteristics of an established cell line of retinoblastoma. J Natl Cancer Inst 1974, 53:347-360.
22. McFall R.C., Sery T.W., Makadon M. Characterization of a new continuous cell line derived from a human retinoblastoma. Cancer Res 1977, 37:1003-1010.
23. Schmidt-Erfurth U., Diddens H., Birngruber R., Hasan T. Photodynamic targeting of human retinoblastoma cells using covalent low-density lipoprotein conjugates. Br J Cancer 1997, 75:54-61.
24. Laville I., Pigaglio S., Blais J.C., et al. Photodynamic efficiency of diethylene glycol-linked glycoconjugated porphyrins in human retinoblastoma cells. J Med Chem 2006, 49:2558-2567.
25. Casilli F., Di Rocco Z.C., Gad S., et al. Rapid detection of novel BRCA1 rearrangements in high-risk breast-ovarian cancer families using multiplex PCR of short fluorescent fragments. Hum Mutat 2002, 20:218-226.
26. Mairal A., Pinglier E., Gilbert E., et al. Detection of chromosome imbalances in retinoblastoma by parallel karyotype and CGH analyses. Genes Chromosomes Cancer 2000, 28:370-379.
27. Gallie B.L., Campbell C., Devlin H., Duckett A., Squire J.A. Developmental basis of retinal-specific induction of cancer by RB mutation. Cancer Res 1999, 59:1731s-1735s.
28. Stephan H., Boeloeni R., Eggert A., Bornfeld N., Schueler A. Photodynamic therapy in retinoblastoma: effects of verteporfin on retinoblastoma cell lines. Invest Ophthalmol Vis Sci 2008, 49:3158-3163.
29. Yan Y., Dunkel I.J., Guan X., Abramson D.H., Jhanwar S.C., O'Reilly R.J. Engraftment and growth of patient-derived retinoblastoma tumour in severe combined immunodeficiency mice. Eur J Cancer 2000, 36:221-228.
30. Gallie B.L., Albert D.M., Wong J.J., Buyukmihci N., Pullafito C.A. Heterotransplantation of retinoblastoma into the athymic "nude" mouse. Invest Ophthalmol Vis Sci 1977, 16:256-259.
31. Dyer M.A., Rodriguez-Galindo C., Wilson M.W. Use of preclinical models to improve treatment of retinoblastoma. PLoS Med 2005, 2:e332.
32. Cowell J.K., Ramani P., Song Y., Evans M., Morgan G. The use of SCID mice for the growth of retinoblastoma cell lines and for the establishment of xenografts from primary tumours. Eur J Cancer 1997, 33:1070-1074.
33. Zhang J., Schweers B., Dyer M.A. The first knockout mouse model of retinoblastoma. Cell Cycle 2004, 3:952-959.
34. del Cerro M., Seigel G.M., Lazar E., et al. Transplantation of Y79 cells into rat eyes: an in vivo model of human retinoblastomas. Invest Ophthalmol Vis Sci 1993, 34:3336-3346.
35. Clarke A.R., Maandag E.R., van Roon M., et al. Requirement for a functional Rb-1 gene in murine development. Nature 1992, 359:328-330.
36. Jacks T., Fazeli A., Schmitt E.M., Bronson R.T., Goodell M.A., Weinberg R.A. Effects of an Rb mutation in the mouse. Nature 1992, 359:295-300.
37. Madreperla S.A., Bookstein R., Jones O.W., Lee W.H. Retinoblastoma cell lines Y79, RB355 and WERI-Rb27 are genetically related. Ophthalmic Paediatr Genet 1991, 12:49-56.
38. Heinzelmann-Schwarz V., Fedier A., Hornung R., Walt H., Haller U., Fink D. Role of p53 and ATM in photodynamic therapy-induced apoptosis. Lasers Surg Med 2003, 33:182-189.
39. Sastre X., Chantada G.L., Doz F., et al. Proceedings of the consensus meetings from the International Retinoblastoma Staging Working Group on the pathology guidelines for the examination of enucleated eyes and evaluation of prognostic risk factors in retinoblastoma. Arch Pathol Lab Med 2009, 133:1199-1202.
40. Khelfaoui F., Validire P., Auperin A., et al. Histopathologic risk factors in retinoblastoma: a retrospective study of 172 patients treated in a single institution. Cancer 1996, 77:1206-1213.
41. Houdayer C., Gauthier-Villars M., Lauge A., et al. Comprehensive screening for constitutional RB1 mutations by DHPLC and QMPSF. Hum Mutat 2004, 23:193-202.
42. Bourdon O., Laville I., Carrez D., et al. Biodistribution of meta-tetra(hydroxyphenyl)chlorin incorporated into surface-modified nanocapsules in tumor-bearing mice. Photochem Photobiol Sci 2002, 1:709-714.
43. Cramers P., Ruevekamp M., Oppelaar H., Dalesio O., Baas P., Stewart F.A. Foscan uptake and tissue distribution in relation to photodynamic efficacy. Br J Cancer 2003, 88:283-290.
44. Lees E., Faha B., Dulic V., Reed S.I., Harlow E. Cyclin E/cdk2 and cyclin A/cdk2 kinases associate with p107 and E2F in a temporally distinct manner. Genes Dev 1992, 6:1874-1885.
45. Zielinski B., Gratias S., Toedt G., et al. Detection of chromosomal imbalances in retinoblastoma by matrix-based comparative genomic hybridization. Genes Chromosomes Cancer 2005, 43:294-301.
46. Brown D.M., Kaiser P.K., Michels M., et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006, 355:1432-1444.
47. Veenhuizen R., Oppelaar H., Ruevekamp M., Schellens J., Dalesio O., Stewart F. Does tumour uptake of Foscan determine PDT efficacy?. Int J Cancer 1997, 73:236-239.
48. Bautista-Sanchez A., Kasselouri A., Desroches M.C., et al. Photophysical properties of glucoconjugated chlorins and porphyrins and their associations with cyclodextrins. J Photochem Photobiol B 2005, 81:154-162.
49. Laville I., Figueiredo T., Loock B., et al. Synthesis, cellular internalization and photodynamic activity of glucoconjugated derivatives of tri and tetra(meta-hydroxyphenyl)chlorins. Bioorg Med Chem 2003, 11:1643-1652.
50. Laville I., Pigaglio S., Blais J.C., et al. A study of the stability of tri(glucosyloxyphenyl)chlorin, a sensitizer for photodynamic therapy, in human colon tumoural cells: a liquid chromatography and MALDI-TOF mass spectrometry analysis. Bioorg Med Chem 2004, 12:3673-3682.
51. Bourdon O., Mosqueira V., Legrand P., Blais J. A comparative study of the cellular uptake, localization and phototoxicity of meta-tetra(hydroxyphenyl) chlorin encapsulated in surface-modified submicronic oil/water carriers in HT29 tumor cells. J Photochem Photobiol B 2000, 55:164-171.
52. Lupu M., Thomas C.D., Maillard P., et al. 23Na MRI longitudinal follow-up of PDT in a xenograft model of human retinoblastoma. Photodiagnosis Photodyn Ther 2009, 6:214-220.